Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
VISEN Pharmaceuticals ( (HK:2561) ) has provided an announcement.
VISEN Pharmaceuticals has announced a supplemental notice for its annual general meeting to be held in Shanghai, China. The company will consider an ordinary resolution to approve a commercial supply framework agreement with Ascendis Europe and the grant of 435,000 award shares to its CEO, Mr. LU An-Bang. These resolutions are part of the company’s strategic initiatives to enhance its operational capabilities and reward leadership, potentially impacting its market positioning and stakeholder interests.
More about VISEN Pharmaceuticals
VISEN Pharmaceuticals is a company incorporated in the Cayman Islands with limited liability, operating in the pharmaceutical industry. The company focuses on developing and commercializing innovative therapies for endocrine-related diseases.
Average Trading Volume: 175,119
Learn more about 2561 stock on TipRanks’ Stock Analysis page.